Orthovita's Rhakoss enters spinal implant trials:
This article was originally published in Clinica
Orthovita is pressing ahead with plans to support an application for European approval of its Rhakoss synthetic bone spinal implant by starting clinical trials of the device. The trials are to include the study of the product in 75 patients undergoing cervical spinal fusion surgery. Rhakoss is made of Orthobone, a proprietary biomaterial developed by Malvern, Pennsylvania-based Orthovita. It is designed to provide a synthetic alternative to structural cadaver bone with unique bioactive and bone bonding characteristics, says the company.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.